Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bifidobacterium (mixed strains) has been studied for its potential to support or treat infections, particularly those of the gastrointestinal tract. Scientific evidence suggests that certain strains of Bifidobacterium can modulate the immune system, enhance the integrity of the gut barrier, and inhibit the growth of pathogenic bacteria through competitive exclusion and the production of antimicrobial substances. Clinical trials have demonstrated benefits in reducing the duration and severity of infectious diarrhea, including that caused by rotavirus in children and antibiotic-associated diarrhea in adults. A 2016 meta-analysis published in the journal Gastroenterology concluded that Bifidobacterium-containing probiotics can reduce the risk of Clostridium difficile-associated diarrhea in both adults and children. Additionally, some studies indicate a possible role in preventing respiratory tract infections, though the evidence here is less robust and often involves mixed probiotic formulations.

While the overall quality of evidence is moderate, with some heterogeneity in study design and probiotic strains used, the use of Bifidobacterium as an adjunct to standard infection management—especially for gastrointestinal infections—has scientific support. However, it is important to note that efficacy depends on the specific strains and dosages involved, and probiotics should not be considered a replacement for standard medical therapies in acute infections.

More about Bifobacterium (mixed)
More about Infection

Other ingredients used for Infection

Other health conditions supported by Bifobacterium (mixed)

Products containing Bifobacterium (mixed)